Bibliometric data in clinical cardiology revisited. The case of 37 Dutch professors

T Opthof1, A A M Wilde

  • 1Department of Clinical and Experimental Cardiology, Heart Failure Research Center, Academic Medical Center, Meibergdreef 9, Room K2-105, 1105 AZ, Amsterdam, the Netherlands, t.opthof@inter.nl.net.

Insights

Bibliometric parameters like the Hirsch index (h-index) are inconsistent for evaluating clinical cardiology professors. Current citation metrics lack reliability for science policy, especially across different medical fields.

Area of Science:

  • Cardiology
  • Bibliometrics
  • Scientometrics

Background:

  • Bibliometric indicators are increasingly used in academic evaluation and science policy.
  • The Hirsch index (h-index) is a common metric, but its suitability for diverse scientific fields remains debated.
  • Assessing the utility of bibliometric parameters within specialized medical fields is crucial.

Purpose of the Study:

  • To evaluate the bibliometric performance of 37 Dutch professors in clinical cardiology.
  • To determine the consistency of various bibliometric parameters (h-index, first-authored h-index, paper count, citation count, citations per paper) in ranking these experts.
  • To assess the suitability of current bibliometric parameters for science policy decisions in medicine.

Main Methods:

  • Compilation of bibliometric data for 37 Dutch clinical cardiology professors.
  • Calculation of five key parameters: overall h-index, first-authored h-index, total publications, total citations, and average citations per paper.
  • Generation of top 10 lists for each parameter to compare the consistency of rankings.

Main Results:

  • Only 22 out of 37 professors appeared in at least one of the five top 10 lists, indicating significant parameter variability.
  • No single bibliometric parameter consistently identified the same group of leading professors.
  • Considerable inhomogeneity in citation characteristics was observed even within this specialized group.

Conclusions:

  • Current bibliometric parameters are not sufficiently robust or reliable for evaluating individual scientists or informing science policy, particularly in specialized medical fields.
  • The observed increase in publications per author may reflect increased collaboration and network effects rather than genuine productivity gains.
  • Citation analysis requires cautious application, especially when comparing diverse medical disciplines within academic institutions.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...